PE20090284A1 - Formulacion de soluciones de sucrosa para ultracentrifugacion continua para purificacion de virus - Google Patents

Formulacion de soluciones de sucrosa para ultracentrifugacion continua para purificacion de virus

Info

Publication number
PE20090284A1
PE20090284A1 PE2008000785A PE2008000785A PE20090284A1 PE 20090284 A1 PE20090284 A1 PE 20090284A1 PE 2008000785 A PE2008000785 A PE 2008000785A PE 2008000785 A PE2008000785 A PE 2008000785A PE 20090284 A1 PE20090284 A1 PE 20090284A1
Authority
PE
Peru
Prior art keywords
sucrosa
formulation
solutions
sugar
virus purification
Prior art date
Application number
PE2008000785A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of PE20090284A1 publication Critical patent/PE20090284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Abstract

REFERIDA A UNA FORMULACION DE UN AZUCAR QUE CONSISTE DE UNA GRADIENTE DE AZUCAR ESTABLECIDA POR UNA CAPA A DEL AZUCAR A UNA CONCENTRACION DE UN EQUIVALENTE DE SUCROSA DE 38% A 46% (p/p) Y UNA CAPA B DE AZUCAR EN UNA CONCENTRACION DE UN EQUIVALENTE DE SUCROSA DE 50% A 60% (p/p) Y UN REGULADOR ACUOSO. DICHA SOLUCION ES UTIL EN LA PURIFICACION DE VIRUS O ANTIGENOS VIRALES TALES COMO ORTHOMYXOVIRUS O VIRUS DE INFLUENZA
PE2008000785A 2007-05-04 2008-05-05 Formulacion de soluciones de sucrosa para ultracentrifugacion continua para purificacion de virus PE20090284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
PE20090284A1 true PE20090284A1 (es) 2009-03-17

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000785A PE20090284A1 (es) 2007-05-04 2008-05-05 Formulacion de soluciones de sucrosa para ultracentrifugacion continua para purificacion de virus

Country Status (18)

Country Link
US (4) US20100239609A1 (es)
EP (1) EP2155864B1 (es)
JP (2) JP5745717B2 (es)
KR (4) KR20100017594A (es)
CN (2) CN104694489A (es)
AR (1) AR066449A1 (es)
AU (1) AU2008248904B2 (es)
BR (1) BRPI0811499B8 (es)
CA (1) CA2687119C (es)
CL (1) CL2008001294A1 (es)
HK (2) HK1138318A1 (es)
IL (1) IL201898A (es)
MX (1) MX2009011897A (es)
PE (1) PE20090284A1 (es)
RU (1) RU2503719C2 (es)
TW (1) TWI472620B (es)
WO (1) WO2008135229A2 (es)
ZA (1) ZA200907743B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811499B8 (pt) * 2007-05-04 2021-05-25 Baxalta GmbH métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
CA2750055A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
JP6719468B2 (ja) 2014-12-16 2020-07-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 大規模なウイルス精製方法
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
PT3535388T (pt) 2016-11-04 2023-06-27 Takeda Pharmaceuticals Co Métodos de purificação de vírus adeno-associados
CN110352353B (zh) 2017-03-03 2023-12-15 武田药品工业株式会社 确定腺相关病毒制剂的效价的方法
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
EP4330270A2 (en) 2021-04-30 2024-03-06 Takeda Pharmaceutical Company Limited Aav8 capsid variants with enhanced liver targeting
CA3234817A1 (en) * 2021-10-12 2023-04-20 Remo MOOMIAIE Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
EP0005408B1 (en) 1978-05-08 1982-12-01 Merck & Co. Inc. A process for the direct extraction of small size particles of up to 50 nm from a protein aceous liquid
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
BRPI0811499B8 (pt) * 2007-05-04 2021-05-25 Baxalta GmbH métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Also Published As

Publication number Publication date
KR20100017594A (ko) 2010-02-16
CL2008001294A1 (es) 2009-03-06
KR101998537B1 (ko) 2019-07-09
JP2015061538A (ja) 2015-04-02
US20160060603A1 (en) 2016-03-03
JP5745717B2 (ja) 2015-07-08
KR20170065671A (ko) 2017-06-13
MX2009011897A (es) 2010-02-04
KR20150082676A (ko) 2015-07-15
HK1211320A1 (en) 2016-05-20
AU2008248904A1 (en) 2008-11-13
US9732327B2 (en) 2017-08-15
US8969533B2 (en) 2015-03-03
BRPI0811499B8 (pt) 2021-05-25
AU2008248904B2 (en) 2014-10-09
HK1138318A1 (en) 2010-08-20
RU2503719C2 (ru) 2014-01-10
IL201898A (en) 2013-11-28
CN101688187A (zh) 2010-03-31
US20100239609A1 (en) 2010-09-23
CA2687119A1 (en) 2008-11-13
BRPI0811499A2 (pt) 2014-10-14
TWI472620B (zh) 2015-02-11
US20080274138A1 (en) 2008-11-06
US20170369853A1 (en) 2017-12-28
EP2155864B1 (en) 2013-07-17
JP6031082B2 (ja) 2016-11-24
TW200914615A (en) 2009-04-01
ZA200907743B (en) 2010-09-29
KR101873891B1 (ko) 2018-07-04
WO2008135229A2 (en) 2008-11-13
IL201898A0 (en) 2011-08-01
JP2010525798A (ja) 2010-07-29
WO2008135229A3 (en) 2008-12-31
RU2009144980A (ru) 2011-06-10
KR101744430B1 (ko) 2017-06-20
AR066449A1 (es) 2009-08-19
EP2155864A2 (en) 2010-02-24
CA2687119C (en) 2021-06-08
BRPI0811499B1 (pt) 2019-06-04
KR20180077305A (ko) 2018-07-06
CN104694489A (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
PE20090284A1 (es) Formulacion de soluciones de sucrosa para ultracentrifugacion continua para purificacion de virus
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CR20130620A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
CL2015003117A1 (es) Modificaciones en la estructura cristalina
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
ECSP14013189A (es) Inhibidores de la replicación de los virus de la gripe
SV2015004979A (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contiene un grupo sulfoximina
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
UY32717A (es) Inhibidores de la replicación de virus de la gripe
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
CL2011002286A1 (es) Uso de compuestos derivados de nucleosidos para tratar una enfermedad viral; compuestos derivados de nucleosidos; y composicion farmaceutica que comprende los compuestos.
CL2013000083A1 (es) Compuestos derivados de pirimidinas y triazinas condensadas; procedimiento para prepararlos; medicamento que los comprende; procedimiento de tratamiento y/o prevencion; y su uso para el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, hipertension pulmonar e isquemias, entre otras enfermedades.
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112013026427A2 (pt) inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos
BR112015007616A2 (pt) inibidores de mek no tratamento de doenças por vírus
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
BR112014021065A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
AR103838A1 (es) Variantes de protoxina-ii y métodos de uso
PE20151142A1 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina

Legal Events

Date Code Title Description
FC Refusal